Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review.

Autor: Nepal G; Department of Internal Medicine, Tribhuvan University Institute of Medicine, Maharajgunj, Kathmandu 44600, Nepal., Khurana M; Department of Public Health, Berkeley Public Health Division, Berkeley, CA 94704, USA., Bucheli DH; Department of Medicine, Universidad Internacional de Ecuador, Loja 110150, Ecuador., Bhandari S; Department of Internal Medicine, Tribhuvan University Institute of Medicine, Maharajgunj, Kathmandu 44600, Nepal., Joshi U; Department of Internal Medicine, Rochester General Hospital, Rochester, NY 14621, USA., Bhagat R; Department of Neurology, Boston University Medical Center, Boston, MA 02118, USA., Rehrig JH; Department of Neurology, North Shore University Hospital, Manhasset, NY 11030, USA., Pudasainee P; Department of Internal Medicine, AMITA Health Saint Francis Hospital, Evanston, IL 60202, USA., Shing YK; Department of Internal Medicine, National University Hospital, Singapore 119074, Singapore., Ortiz JF; Department of Neurology, California Institute of Behavioral Neuroscience & Psychology, Fairfield, CA 94534, USA., Ojha R; Department of Neurology, Tribhuvan University Teaching Hospital, Kathmandu 44600, Nepal., Gajurel BP; Department of Neurology, Tribhuvan University Teaching Hospital, Kathmandu 44600, Nepal., Quinonez J; Department of Neurology, Larkin Community Hospital, South Miami, FL 100181, USA.; Department of Osteopathic Neuromuscular Medicine, Larkin Community Hospital, Miami, FL 100181, USA., Ruxmohan S; Department of Neurology, Larkin Community Hospital, South Miami, FL 100181, USA., Albert T; Department of Osteopathic Neuromuscular Medicine, Larkin Community Hospital, Miami, FL 100181, USA., Licata S; Department of Osteopathic Neuromuscular Medicine, Larkin Community Hospital, Miami, FL 100181, USA., Stien J; Department of Osteopathic Neuromuscular Medicine, Larkin Community Hospital, Miami, FL 100181, USA.
Jazyk: angličtina
Zdroj: Neurology international [Neurol Int] 2022 Jan 11; Vol. 14 (1), pp. 99-108. Date of Electronic Publication: 2022 Jan 11.
DOI: 10.3390/neurolint14010009
Abstrakt: Primary Central Nervous System Lymphoma (PCNSL) is a rare variant of Non-Hodgkin Lymphoma (NHL) representing 1-2% of all NHL cases. PCNSL is defined as a lymphoma that occurs in the brain, spinal cord, leptomeninges, or eyes. Efforts to treat PCNSL by traditional chemotherapy and radiotherapy have generally been unsuccessful as a significant proportion of patients have frequent relapses or are refractory to treatment. The prognosis of patients with Refractory or Relapsed (R/R) PCNSL is abysmal. The optimal treatment for R/R PCNSL is poorly defined as there are only a limited number of studies in this setting. Several studies have recently shown that ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, has promising results in the treatment of R/R PCNSL. However, these are preliminary studies with a limited sample size. In this systematic review, we explored and critically appraised the evidence about the efficacy of the novel agent ibrutinib in treating R/R PCNSL.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje